Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06409195 · ClinicalTrials.gov registry record · Phase 2
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
A Phase 2 study of Non-Melanoma Skin Cancers, sponsored by DermBiont.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06409195 is a Phase 2 study of Non-Melanoma Skin Cancers that is actively recruiting participants, run by DermBiont. The registered enrollment target is 50 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06409195, a Phase 2 study of Non-Melanoma Skin Cancers, is actively recruiting participants, sponsored by DermBiont.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Open-Label study evaluating safety and efficacy of SM-020 Gel 1.0% in subjects with Seborrheic Keratoses and Non-Melanoma Skin Cancers (i.e. Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ). Subjects will be enrolled into 1 of 5 cohorts. Each cohort will enroll approximately 5-10 subjects with at least 1 eligible lesion to be treated. A maximum of 5 lesions may be enrolled per subject. Treatment for all subjects and all lesions will be twice daily for approximately 28 days. Post treatment, residual lesions may be excised per standard of care for histological evaluation. The duration of the study is estimated to be approximately up to 12 weeks from the beginning of the Screening period until the last subject's last visit.
Conditions Studied
Interventions
- DRUG SM-020 1% Gel
Study Locations (1)
North Carolina
- Dermatology, Laser and Vein Specialist - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-03-25 |
| Est. Completion | 2024-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06409195
The ClinicalTrials.gov registry entry for NCT06409195 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DermBiont, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Melanoma Skin Cancers appearing as the primary indexed condition, and to 1 intervention - of which SM-020 1% Gel is the first listed.
NCT06409195 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06409195 about?
NCT06409195 is a clinical study titled "A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers". Open-Label study evaluating safety and efficacy of SM-020 Gel 1.0% in subjects with Seborrheic Keratoses and Non-Melanoma Skin Cancers (i.e. Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ). Subjects will be enrolled into 1 of 5 cohorts. Each cohort will enroll approximately 5-10 subjects w...
What is the current status of trial NCT06409195?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-03-25. Estimated completion is 2024-11.
What conditions does trial NCT06409195 study?
This clinical trial studies the following conditions: Non-Melanoma Skin Cancers.
What interventions are being tested in trial NCT06409195?
The interventions under investigation include: SM-020 1% Gel (DRUG).
Who is sponsoring clinical trial NCT06409195?
This trial is sponsored by DermBiont, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06409195 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.